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To the Editor:
B-cell receptor (BCR) signaling pathway inhibitors
(including Bruton’s tyrosine kinase [BTK] inhibitors, and
phosphatidylinositol-3 kinase inhibitors [PI3Ki]) have
shown clinical efficacy in non-Hodgkin lymphoma (NHL).
However, responses to these agents have been limited in
depth and duration. This may be due to resistance to PI3Kδ
and BTK inhibitors as monotherapy [1–5]. The emergence
of resistant clones may be addressed by combining these 2
classes of drugs. Furthermore, tolerability of these drug
classes has been a concern. Combination therapy using
lower doses of one or more classes of inhibitors may
address some limitations.
Tirabrutinib (TIRA, formerly ONO/GS-4059) is a
selective, irreversible, and small-molecule BTK inhibitor
[6, 7]. TIRA has greater target selectivity compared with
ibrutinib, which is characterized by high-affinity inhibition
of ten kinases other than BTK [8]. In two separate phase
1 studies, TIRA was evaluated for treatment of patients with
follicular lymphoma (FL), non-germinal center B-cell (non-
GCB) diffuse large B-cell lymphoma (DLBCL), mantle cell
lymphoma (MCL), and lymphoplasmacytic lymphoma
(LPL) [7, 9]. Response rates were 20–100% across disease
types, with a favorable safety profile [7, 9]. The only car-
diovascular adverse events (AEs) were atrial fibrillation/
flutter, which occurred in 5 of the 107 patients in the
2 studies, 4 of whom had this as a pre-existing medical
condition.
We assessed the combination of TIRA with a PI3Kδ
inhibitor (idelalisib [IDELA]) or a SYK inhibitor (entos-
pletinib [ENTO]). IDELA is a first-in-class PI3Kδ inhibitor
approved for the treatment of relapsed or refractory (R/R)
chronic lymphocytic leukemia (CLL), small lymphocytic
lymphoma (SLL), and FL in the US and Europe [10].
Response rates were 54% and 58% in FL and SLL,
respectively [10]. ENTO (formerly GS-9973) is an inves-
tigational selective noncovalent inhibitor of SYK. In a
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study of patients with FL, LPL, MCL, and marginal zone
lymphoma (MZL), treatment with ENTO 800 mg twice
daily resulted in response rates ranging from 12% to 35%,
with manageable toxicity [11].
The present study was designed to evaluate the safety of
TIRA/IDELA and TIRA/ENTO combinations and define
the maximum tolerated dose (MTD) for each combination
and preliminary efficacy in patients with selected subtypes
of NHL and CLL. The results from CLL patients have been
reported elsewhere [12]. Herein, we report results in NHL
patients.
This was a phase 1b, open-label, multicenter, sequential
dose-escalation and -expansion study in patients with R/R
NHL (NCT02457598). Eligible patients had a diagnosis of
non-GCB DLBCL, FL, MCL, or other indolent NHL
(MZL, SLL, or LPL) as documented by medical records.
Patients had a history of ≥1 prior therapy (but no prior
exposure to BTK or PI3K inhibitors), were not transplant
eligible, and had either progressive disease (PD) or no
response (stable disease) on their most recent treatment
regimen. Except for those with LPL, patients had a radi-
ologically measurable presence of ≥1 lymph node lesions.
Patients were treated with TIRA ranging from 20 mg to
160 mg QD in combination with IDELA (50 mg BID or
100 mg QD) or ENTO (200 mg QD or 400 mg QD)
according to a standard 3+ 3 dose-escalation schema
(Supplementary Table 1).
The primary endpoint was safety, evaluated by the
occurrence of AEs, and laboratory abnormalities defined as
dose-limiting toxicities (Supplementary Table 2). Pre-
liminary efficacy was evaluated by overall response rate
(ORR). Secondary endpoints included pharmacokinetic
(PK) parameters, progression-free survival (PFS), duration
of response, time to response, and proportion of patients
achieving both complete response and undetectable minimal
residual disease (MRD). Patients had CT or MRI scans
every 12 weeks; those with DLBCL had an additional scan
at week 6. Further details on study methods are provided in
the Supplementary Methods.
Overall, 40 patients were treated with TIRA/IDELA and
91 with TIRA/ENTO (Supplementary Fig. 1). Patient
characteristics and baseline demographics of the NHL
subtypes included in this study are shown in Table 1. Forty-
seven percent of DLBCL patients in the TIRA/IDELA
group were refractory to their last prior regimen; 67% were
refractory to prior regimens in the TIRA/ENTO group. In
the TIRA/IDELA group, 70% of FL patients had failed ≥2
prior therapies, and 50% had failed both rituximab/anti-
CD20+ and alkylating regimens. Eighty percent were
refractory to their last prior treatment regimen before
enrolling in this study, with stable disease or PD as the best
prior response. In the TIRA/ENTO group, most patients
were relapsed rather than refractory, with 65% of FL
patients having achieved a response (27% complete,
38% partial) on their last prior therapy.
Study drug exposures are shown in Supplementary Fig. 2
and Supplementary Table 3. In the TIRA/IDELA and
TIRA/ENTO groups, discontinuations due to AEs occurred
in 10% and 3% of patients, and discontinuations due to PD
occurred in 60% and 48% of patients, respectively. Five
patients on TIRA/IDELA and 6 patients on TIRA/ENTO
died on-study, all due to PD.
In the TIRA/IDELA treatment group, treatment-
emergent AEs (TEAEs) occurred in 100% of patients,
with 38% having serious TEAEs (Table 2). TEAEs leading
to investigator-determined TIRA discontinuation occurred
in 15% of TIRA/IDELA patients. These included anemia,
neutropenia, pancytopenia, atrial fibrillation, and transami-
nase increased (1 patient each), and rash (n= 2). TEAEs
leading to discontinuation of IDELA occurred in 18% of
patients. Grade ≥3 laboratory abnormalities occurred in 69%
of TIRA/IDELA patients. The most common hematologic
and hepatic abnormalities (excluding lymphopenia) were
decreased neutrophils and platelets, and increased liver
enzymes (Supplementary Table 4). One MZL patient
receiving TIRA 20 mg BID+ IDELA 50 mg BID experi-
enced a dose-limiting toxicity (grade 4 neutropenia and
grade 4 thrombocytopenia), and subsequently the protocol
was amended to include only TIRA QD dosing. MTD with
TIRA QD dosing in combination with IDELA was not
reached.
In the TIRA/ENTO treatment group, TEAEs occurred in
95% of patients, with 36% having serious TEAEs (Table 2).
TEAEs leading to investigator-determined TIRA dis-
continuation occurred in 3% of TIRA/ENTO patients.
These included biphasic mesothelioma, lung neoplasm
(malignant), and pancreatitis (one patient each). TEAEs
leading to discontinuation of ENTO occurred in 8% of
patients. Grade ≥3 laboratory abnormalities occurred in 57%
of TIRA/ENTO patients. The most common hematologic
and hepatic abnormalities (excluding lymphopenia) were
decreased neutrophils and platelets, and increased liver
enzymes (Supplementary Table 4). There were no dose-
limiting toxicities in the TIRA/ENTO group and MTD was
not reached.
Efficacy results are reported across all dose groups in
both combinations. Response rates are shown in Supple-
mentary Table 5. In DLBCL patients, response rates were
comparable across both combinations; the ORR was 24%
with TIRA/IDELA and 26% with TIRA/ENTO. The ORR
in patients with FL was 20% with TIRA/IDELA and 35%
with TIRA/ENTO, and in patients with MCL, ORR was
100% with TIRA/IDELA and 64% with TIRA/ENTO. In
patients with other indolent NHL, the ORR was 58% with
TIRA/IDELA and 67% with TIRA/ENTO. The median
(Q1, Q3) time to response and the median (Q1, Q3) duration
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TIRA/IDELA, N 17 10 1 12
Age, median (range) years 72 (37–89) 58 (32–70) 70 (70–70) 68 (41–77)
Female, n (%) 5 (29) 4 (40) 0 5 (42)
Time since diagnosis, median (range) years 1.5 (0.3–7.4) 9.3 (0.3–23.0) 3.3 (3.3–3.3) 6.0 (0.0–9.4)
Ann Arbor staging, n (%)a
I–II 3 (18) – 0 0
III or IV 14 (82) – 1 (100) 11 (92)
Missing 0 – 0 1 (8)
Follicular lymphoma staging, n (%)
Grade 1 – 0 – –
Grade 2 – 7 (70) – –
Grade 3a – 3 (30) – –
Unknown – 0 – –
ECOG performance status, n (%)
0 9 (53) 3 (30) 0 7 (58)
1 8 (47) 7 (70) 1 (100) 2 (25)
≥2 0 0 0 2 (17)
Lactate dehydrogenase, U/L, median (range) 256 (157–924) 256 (176–970) 237 (237–237) 207 (72–411)
Prior no. of anticancer therapies, median (range) 3.0 (1–4) 4.0 (2–6) 2.0 (2–2) 2.5 (2–5)
Best response to last regimen, n (%)
Complete response 2 (12) 0 0 2 (17)
Partial response 5 (29) 1 (10) 1 (100) 1 (8)
Stable disease 2 (12) 4 (40) 0 1 (8)
Progressive disease 6 (35) 4 (40) 0 4 (33)
Unknown 2 (12) 1 (10) 0 3 (25)
N/A 0 0 0 1 (8)
TIRA/ENTO, N 39 26 11 15
Age, median (range) years 69 (30–89) 67 (37–78) 70 (61–90) 68 (58–85)
Female 12 (31) 12 (46) 0 3 (20)
Time since diagnosis, median (range) years 1.7 (0.4–23.7) 6.1 (0.3–37.7) 4.6 (1.5–17.1) 6.1 (1.0–19.1)
Ann Arbor staging, n (%)b
I–II 7 (18) – 1 (9) 3 (20)
III or IV 32 (82) – 9 (82) 10 (67)
Missing 0 – 1 (9) 2 (13)
Follicular lymphoma staging, n (%)
Grade 1 – 3 (12) – –
Grade 2 – 12 (46) – –
Grade 3a – 7 (27) – –
Unknown – 4 (15) – –
ECOG performance status, n (%)
0 19 (49) 17 (65) 5 (46) 10 (67)
1 18 (46) 8 (31) 6 (55) 5 (33)
≥2 2 (5) 1 (4) 0 0
Lactate dehydrogenase, median (range) 250 (131–956) 222 (131–492) 208 (146–408) 156 (107–1107)
Prior no. of anticancer therapies, median (range) 3.0 (1–7) 3.0 (1–12) 3.0 (2–4) 2.0 (1–6)
Best response to last regimen, n (%)
Complete response 7 (18) 7 (27) 4 (36) 3 (20)










Partial response 6 (15) 10 (39) 2 (18) 5 (33)
Stable disease 12 (31) 2 (8) 3 (27) 4 (27)
Progressive disease 14 (36) 5 (19) 0 1 (7)
Unknown 0 2 (8) 1 (9) 2 (13)
N/A 0 0 1 (9) 0
aFifty-five of the 56 DLBCL patients had non-GCB subtype, and 1 patient in the TIRA/IDELA group had GCB subtype (a protocol deviation
resulting from a delayed pathology report).
bFollicular lymphoma grading was missing for 4 patients.






TEAEs, n (%) 40 (100) 86 (95)
TEAEs related to TIRA 31 (78) 70 (77)
TEAEs leading to TIRA discontinuation 6 (15) 3 (3)
TEAEs related to IDELA 31 (78) –
TEAEs leading to IDELA discontinuation 7 (18) –
TEAEs related to ENTO – 64 (70)
TEAEs leading to ENTO discontinuation – 7 (8)
SAEsa, n (%) 15 (38) 33 (36)
SAEs related to TIRA 7 (18) 8 (9)
SAEs related to IDELA 8 (20) –
SAEs related to ENTO – 9 (10)
TEAEs by MedDRA preferred termb TIRA/IDELA TIRA/ENTO
Any grade Grade ≥3 Any grade Grade ≥3
Neutropenia 11 (28) 9 (23) 14 (15) 14 (15)
Diarrhea 9 (23) 1 (3) 23 (25) 0 (0)
Thrombocytopenia 9 (23) 5 (13) 5 (6) 3 (3)
Pyrexia 8 (20) 1 (3) 13 (14) 4 (4)
Cough 8 (20) 0 (0) 10 (11) 0 (0)
Rash 8 (20) 1 (3) 9 (10) 1 (1)
Fatigue 6 (15) 0 (0) 20 (22) 0 (0)
Nausea 6 (15) 0 (0) 15 (17) 0 (0)
Back pain 6 (15) 1 (3) 12 (13) 0 (0)
Contusion 6 (15) 0 (0) 11 (12) 0 (0)
Headache 6 (15) 1 (3) 7 (8) 0 (0)
Vomiting 6 (15) 1 (3) 9 (10) 0 (0)
Decreased appetite 6 (15) 0 (0) 7 (8) 0 (0)
Dyspnea 6 (15) 2 (5) 10 (11) 1 (1)
Rash, maculopapular 6 (15) 4 (10) 2 (2) 1 (1)
Asthenia 2 (5) 0 (0) 21 (23) 1 (1)
MedDRA Medical Dictionary for Regulatory Activities.
aSAEs occurring in ≥2 patients in either treatment group.
bTEAEs are shown according to incidence of any grade event occurring in ≥15% of patients in either
treatment group.
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of response with TIRA/IDELA and TIRA/ENTO for
DLBCL, FL, MCL, and other indolent NHL are shown in
Supplementary Table 5; Kaplan–Meier estimated duration
of response is shown separately for each NHL subgroup in
Supplementary Table 6. A ≥50% sum of the products of the
longest perpendicular diameters (SPD) reduction from
baseline occurred in 29% and 26% of DLBCL patients, in
20% and 35% of FL patients, and in 38% and 42% of
patients with other NHL subtypes (including MCL) on
TIRA/IDELA and TIRA/ENTO, respectively (Supplemen-
tary Fig. 3). PFS is shown in Supplementary Fig. 4 and
MRD status in Supplementary Fig. 5.
The primary objective of this phase 1 study was to assess
the safety and tolerability of the TIRA/IDELA and TIRA/
ENTO combinations. The AE rates were generally com-
parable to those observed in previous studies of TIRA
[7, 9], IDELA [13], or ENTO [14] monotherapy in patients
with NHL. There were no unanticipated safety signals seen
with either treatment combination at all doses, and the MTD
for either combination was not reached. IDELA-associated
toxicities appeared to be less frequent in our study com-
pared to what has been reported previously, possibly due to
the use of lower doses [10]. In particular, no patients
receiving TIRA/IDELA had serious TEAEs of diarrhea,
colitis, or ALT/AST elevation.
The combination of TIRA+ low-dose IDELA induced
responses in only 20% of FL patients, and the combination
of TIRA+ ENTO yielded a 35% response rate. These ORRs
are lower than those observed in other studies of R/R FL,
including treatment with the approved dose of 150mg twice
daily IDELA (54% ORR) [2, 10], copanlisib (40–55% ORR)
[3, 15], and duvelisib (42% ORR) [4]. The suboptimal
responses in the present study may be due to lower IDELA
dosing. Except in the DLBCL cohort, where the 160mg
TIRA QD dose increased IDELA plasma PK exposure
relative to lower TIRA doses due to drug-drug interaction,
no further impact of TIRA on IDELA PK at lower doses, or
additional drug-drug interactions were observed in the study
[12]. Consistent with a previous IDELA dose-ranging study
[13], outcomes in DLBCL patients treated with TIRA/
IDELA (N= 17) suggest that reduced IDELA exposure had
a detrimental impact on efficacy.
The overall hypothesis for this study was to explore
whether combining different BCR-targeted agents at lower
doses than their respective doses in monotherapy offers a
meaningful strategy to increase tolerability while preserving
or improving efficacy. Based on the results of this study, we
conclude that while the explored combinations of TIRA/
IDELA and TIRA/ENTO were overall well tolerated, there
was no meaningful efficacy advantage to be gained with this
approach. It is possible that any advantage achieved in
safety through lower doses may in fact have compromised
efficacy in this study.
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